Funding | Overview
Active grants and sponsored research
Project Date: January 1, 2020 - December 31, 2022
Sponsoring Organization: RUNX1 Research Program and Alex's Lemonade Stand Foundation
Pharmacologic Enhancement of Residual Wild Type RUNX1 Activity in Familial Platelet Disorder with Propensity to Develop Leukemia (FPD/AML)
The goal of this study is test the use of src family kinase inhibitors in preclinical models for use in enhancing the residual wild type RUNX1 activity in patients with heterozygous loss-of-function RUNX1 mutations.